De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vigil Neuroscience Toekomstige groei

Future criteriumcontroles 2/6

Vigil Neuroscience zal naar verwachting groeien in winst en omzet met respectievelijk 15.4% en 73.8% per jaar. De winst per aandeel zal naar verwachting groeien met 30% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -181.5% zijn.

Belangrijke informatie

15.4%

Groei van de winst

30.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	73.8%
Toekomstig rendement op eigen vermogen	-181.5%
Dekking van analisten	Good
Laatst bijgewerkt	17 Sep 2024

Recente toekomstige groei-updates

Recent updates

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

Winst- en omzetgroeiprognoses

NasdaqGS:VIGL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	14	-114	-101	-157	5
12/31/2025	0	-102	-98	-108	7
12/31/2024	N/A	-88	-86	-83	7
6/30/2024	N/A	-84	-70	-70	N/A
3/31/2024	N/A	-83	-70	-70	N/A
12/31/2023	N/A	-83	-71	-70	N/A
9/30/2023	N/A	-79	-73	-72	N/A
6/30/2023	N/A	-76	-72	-71	N/A
3/31/2023	N/A	-73	-70	-69	N/A
12/31/2022	N/A	-68	-66	-65	N/A
9/30/2022	N/A	-63	-66	-65	N/A
6/30/2022	N/A	-56	-61	-61	N/A
3/31/2022	N/A	-50	-53	-53	N/A
12/31/2021	N/A	-43	-40	-39	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VIGL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VIGL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VIGL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van VIGL ( 73.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van VIGL ( 73.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat VIGL binnen 3 jaar verliesgevend zal zijn.

Vigil Neuroscience Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.4% to US$18.57

Price target increased by 10% to US$18.86

Price target decreased by 14% to US$17.13

Recent updates

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Neuroscience, Inc. Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index

Vigil Neuroscience, Inc. announced that it expects to receive $39.99997 million in funding from Sanofi Pasteur Biologics, LLC, Aventis Inc.

Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC

New major risk - Share price stability

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven